Recurrent pleomorphic adenoma: is treatment considerably delayed thus affecting surgical morbidity?. (3rd April 2018)

• Record Type: Journal Article
• Authors: Glikson, Eran; Sagiv, Doron; Mansour, Jobran; Bedrin, Lev; Talmi, Yoav P.; Alon, Eran E.
• Is Part Of: Acta oto-laryngologica. Volume 138:Number 4(2018)
• Page Start: 407
• Page End: 410
• Publication Date: 2018-04-03
• Subjects: Recurrent pleomorphic adenoma -- parotid gland -- parotidectomy -- facial nerve; Otolaryngology -- Periodicals; Ear -- Diseases -- Periodicals; Throat -- Diseases -- Periodicals; Otolaryngology -- Electronic Resources; Otorhinolaryngologic Diseases; 617.8
• DOI: 10.1080/00016489.2017.1398840
• Languages: English
• ISSNs: 0001-6489

Abstract

Abstract: Objective: To examine the incidence of late presentation of patients with recurrent pleomorphic adenoma (RPA) of the parotid gland. Methods: This is a retrospective analysis of patients treated in our center. We examined patients demographics, disease characteristics, treatment, and outcome and as well as the time period length from the first discovery of a recurrent mass until seeking treatment at our clinic and its effect on morbidity. Results: A total of 30 patients were included. 26% underwent initial enucleation in other institutions. In eight patients (26%), the recurrence of the mass was second or higher. The patients average time period length until seeking treatment was 2.48 years, with 33% of patients showing a time period length of over three years. Multifocal tumor, tumor diameter larger than 2 cm and facial nerve involvement were found in 15 (50%), 16 (53.3%) and seven (25%) patients respectively. Patient's delay of presentation by ≥3 years was associated with a tumor size of ≥2 cm (Relative Risk [RR] = 2, p = .02). Patient's delay of presentation by ≥2 years was also associated with a trend towards a higher rate of post-operative facial nerve palsy (RR = 3.37, p = .07, CI = 0.88–12.85). Conclusion: Most patients with RPA were presented late, thus affecting disease extent and surgical morbidity.